News By Tag * Glenn D. Prestwich * Faculty entrepreneurism * Clinical Biomaterial * Regenerative Medicine * More Tags... Industry News * Biotechnology * More Industries... News By Place Country(s) Industry News
| Glenn D. Prestwich to speak at 7th Modern Drug Discovery Summit Oct 19-21 2011 in San Diego, CAGlenn D. Prestwich, Director of the Therapeutic Biomaterials Center, Special Presidential Assistant for Faculty Entrepreneurism and Presidential Professor of Medicinal Chemistry at the University of Utah will give a presentation on GTC's conference.
By: GTC Conference University of Utah, will give a plenary keynote presentation on “Engineering a Clinical Biomaterial for Regenerative Medicine: From Bench to Business” at the 7th Modern Drug Discovery and Development Summit to be held in San Diego, CA on October 19-21, 2011 by GTC. Faculty entrepreneurism is a scholarly activity. Dr. Prestwich will describe how the University of Utah has implemented policies that encourage faculty and student entrepreneurial activities through the Entrepreneurial Faculty Scholars and the Young Entrepreneurial Student Scholars programs. He will also describe a case study for commercialization of a university technology in the area of regenerative medicine. Dr. Prestwich will also discuss how they created a synthetic extracellular matrix (sECM) from hyaluronic acid (HA) that affords highly reproducible, manufacturable, approvable, and affordable biomaterials. The in situ crosslinkable sECM hydrogels can be customized for use with progenitor and mature cell populations obtained many tissues, including skin, fat, liver, heart, brain, muscle, bone, and cartilage. In addition, sECMs have been developed for rapid expansion and recovery of cells in 3-D, and for the bioprinting of engineered tissue constructs. The technology is being commercialized in three fields of use: human medical devices, cell therapy and research tools for 3-D cell culture, and veterinary wound care and adhesion prevention. Dr. Glenn D. Prestwich’s passion for translational research and scholarship led to his appointment as director of the Entrepreneurial Faculty Scholars program at the U of Utah (2008 – current). He has launched over seven small life science companies in the last fifteen years: Clear Solutions Biotech (1994-2001); Echelon Biosciences, Inc. (CSO, 1997-2003); Sentrx Surgical, Inc. (CSO, 2003-2004); Carbylan BioSurgery, Inc. (Palo Alto, CA)(2004-current); The 7th Modern Drug Discovery and Development Summit will bring researchers, lab directors/managers, and industry executives the critical scientific, technology, and business coverage that they need. M3D will offer an in-depth examination of the challenges involved in the dynamic and ever-changing field of drug discovery and development. Over 125 leading industrial and academic experts will present at this three-day summit and is comprised of a half day plenary keynote session and 4 full conferences. The M3D Summit includes the following conferences: 5th Biomarker Discovery and Development 5th Drug Design and Medicinal Chemistry 5th Advances in Stem Cell Discovery and Development 4th Protein Discovery & Therapeutics For more information, please visit www.gtcbio.com End
|
| ||||||||||||||||||||||||||||||||||||||||||||||||